{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-23-015014","form_type":"8-K","ticker":"MBIO","cik":"0001680048","company_name":"MUSTANG BIO, INC.","filed_at":"2023-08-16T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.835973+00:00","generated_at":"2026-06-11T08:33:30.157567+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Mustang Bio reports 4 of 4 indolent lymphoma patients respond to MB-106 CAR T; dose escalation approved","bullets":["Clinical responses in 4 of 4 indolent lymphoma patients at starting dose 3.3x10^6 CAR T cells/kg; 2 follicular lymphoma patients achieved CR.","Safety Review Committee unanimously approved dose escalation to 1.0x10^7 CAR T cells/kg; only Grade 1 CRS reported.","Fred Hutch trial (n=20 FL) shows 95% ORR, 80% CR; first patient sustained CR >3 years.","Waldenstrom macroglobulinemia cohort (n=6): 2 CR, one ongoing >22 months; no CRS/ICANS >Grade 2.","Pivotal Phase 2 for WM to start mid-2024, top-line data mid-2026; end-of-Phase 1 FDA meeting expected end of 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-23-015014","json":"https://secwatch.observer/filing/0001558370-23-015014.json","markdown":"https://secwatch.observer/filing/0001558370-23-015014.md","text":"https://secwatch.observer/filing/0001558370-23-015014.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1680048/000155837023015014/0001558370-23-015014-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1680048/000155837023015014/tmb-20230816x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T08:33:30.157567+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}